MedWatch

Danish bank eyes uncertainties for Demant in 2022

A sales halt of cochlear implants and predicted negative growth in France are behind some of the doubts about Demant’s 2022 guidance, writes an analyst from Jyske Bank.

Photo: Simon Fals

Danish bank Jyske Bank regards hearing aid manufacturer Demant’s half-year results from 2021 in a positive light, and therefore also the company’s full-year results, but several factors have caused some concerns about the company’s expectations for 2022, writes the bank’s senior equity analyst, Janne Vincent Kjær.

Jyske Bank is therefore lowering its share price target to DKK 360 (USD 54) from DKK 385 (USD 58), but the bank is maintaining its recommendation ”buy,” the analyst notes in an analysis on Monday morning.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs